Interstitial Lung DiseaseP4O2-ILDNCT06644144
P4O2 ILD Extension
An observational study of Interstitial Lung Disease and Pulmonary Fibrosis, run by Amsterdam UMC, location VUmc at 1 site in Netherlands.
Trial summary
The goal of this observational study is to identify early biomarkers that can predict the development of progressive pulmonary fibrosis (PPF) in participants with interstitial lung diseases (ILDs). Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Interstitial Lung Disease, Pulmonary Fibrosis, Interstitial Lung Fibrosis
- How many people
- 450 participants
- Where
- 1 siteNetherlands
- Study dates
- 1 Nov 2024to 1 Oct 2031
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The P4O2 ILD-extension is a non-interventional prospective observational cohort study that will include a minimum of 450 participants, divided intro three groups (1) 150 participants diagnosed with idiopathic pulmonary fibrosis (IPF) or familial pulmonary fibrosis (FPF); (2) 150 participants diagnosed with other fibrotic ILDs (fILD), including fibrotic hypersensitivity pneumonitis (fHP), idiopathic non-specific interstitial pneumonia (iNSIP), connective tissue disease (CTD)-ILD, and unclassifiable ILD (uILD); and (3) 150 participants diagnosed with interstitial lung abnormalities (ILA).
Who may be able to join
- Diagnosis of (1) idiopathic pulmonary fibrosis (IPF), familial pulmonary fibrosis (FPF), (2) other fibrotic ILDs (fILD), including fibrotic hypersensitivity pneumonitis (fHP), idiopathic non-specific interstitial pneumonia (iNSIP), connective tissue disease (CTD)-ILD, and unclassifiable ILD (uILD); or (3) interstitial lung abnormalities (ILA).
- Meeting all the following criteria during the screening period:
- FVC ≥45% predicted.
- FEV1/FVC ≥0.7.
- DLco corrected for Hb ≥40% predicted.
- Able to provide written informed consent as approved by the independent ethics committee.
Show all 9Show fewer
- Able to undergo a CT scan and perform PFT.
- Age \> 18 years and \< 80 years.
- Understanding of the Dutch or English language.
Who cannot join
- Combined pulmonary fibrosis and emphysema (CPFE) diagnosis
- Chronic obstructive lung disease (COPD) with an FEV1/FVC \<70%.
- Uncontrolled severe asthma.
- Active malignancy, except for squamous cell carcinoma of the skin, low-risk breast cancer, and low-risk prostate cancer.
- Pregnancy or lactating.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Netherlands1 site, 1 recruiting
- Recruiting
Amsterdam UMC, locatie VUmc
Amsterdam, North Holland, 1081 HV
Iris Simons, MD, i.simons@amsterdamumc.nl
About this study
Official title: Early Identification of Progressive Pulmonary Fibrosis, Precision Medicine for More Oxygen - ILD Extension.
The goal of this observational study is to identify early biomarkers that can predict the development of progressive pulmonary fibrosis (PPF) in participants with interstitial lung diseases (ILDs). The participant population includes adults diagnosed with idiopathic pulmonary fibrosis (IPF), familial pulmonary fibrosis (FPF), other fibrotic ILDs, and interstitial lung abnormalities (ILA).
The main questions it aims to answer are:
Read more
- What biomarkers and risk factors are linked to fibrosis progression or can predict rapid worsening and sudden flare-ups in IPF and FPF patients?
- What biomarkers and risk factors can predict the development of a PPF phenotype in different types of ILD?
- What biomarkers and risk factors can help identify ILA patients who may develop significant ILD?
- What biomarkers and risk factors can predict how well ILD patients will respond to treatment?
Researchers will compare the outcomes between participants diagnosed with IPF/FPF, other fibrotic ILDs, and ILA to see if early detection biomarkers differ among these groups.
Participants will:
- Undergo blood sampling.
- Perform lung function tests.
- Have CT scans.
- Perform breath analysis
- Participate in exposome and microbiome analyses.
- Complete questionnaires.
- A subgroup of participants will be offered bronchoscopy.
Read the detailed description
Included participants will complete several study visits to collect clinical data and biological samples. Study visits will be performed at baseline, 3, 6, 12, 24, 36, 48 and 60 months, with a 2-month time window for follow-up visits. These time points are aligned with the standard clinical follow-up visits outlined in the ILD Care Path Protocol of Amsterdam UMC.
- Conditions
- Interstitial Lung Disease, Pulmonary Fibrosis, Interstitial Lung Fibrosis, IPF, Pulmonary Fibrosis, Idiopathic, Pulmonary Fibrosis Idiopathic Familial
- Being tested
- No Interventions
- Keywords
- Interstitial Lung Disease, Interstitial Lung Abnormalities, Progressive Pulmonary Fibrosis
- Medical subject headings
- Lung Diseases, Interstitial, Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
No InterventionsOther
No intervention so not applicable.
| Study group | Role | What they receive |
|---|---|---|
| Idiopathic Pulmonary Fibrosis/Familial Pulmonary Fibrosis | Not described Receives: Other: No Interventions | |
| fibrotic ILD | Patients with a diagnosis of: chronic Hypersensitivity Pneumonitis (cHP), unclassifiable ILD (uILD), idiopathic NSIP or CTD-ILD. Receives: Other: No Interventions | |
| Interstitial Lung Abnormalities | Not described Receives: Other: No Interventions |
What is being measured
The primary outcome is the main question the study is designed to answer.
Inflammatory and fibrosis extent assessed by HRCT
High-Resolution Computed Tomography (HRCT) is an advanced imaging technique used to obtain detailed images of the lungs and chest. Unlike standard CT scans, HRCT uses thin slices and special algorithms to produce high-resolution images that provide more precise visualization of lung structures, making it particularly useful for diagnosing and evaluating various lung conditions. The Inflammatory and Fibrosis extent will be analyzed by using artificial intelligence software.
Measured: A baseline HRCT scan will be performed during screening. Following inclusion in the study, HRCT scans will be repeated annually, starting one year after the initial scan, and continuing each year until the end of follow-up (at 5 years))
Pulmonary function tests (PFTs)- Spirometry volumes
Pulmonary function tests (PFTs) are a group of tests that measure how well your lungs are working. These tests assess lung volume, capacity, rates of flow, and gas exchange. We will look at the following values:
- Spirometry Values
- Forced Vital Capacity (FVC): The total amount of air exhaled after taking the deepest breath possible.
- Forced Expiratory Volume in 1 Second (FEV1): The amount of air forcefully exhaled in one second.
Measured: It will be measured at baseline, at 3, 6, and 12 months, and every other year till end of follow-up (60months))
Pulmonary function tests (PFTs)- DLCO measurement
Pulmonary function tests (PFTs) are a group of tests that measure how well your lungs are working. These tests assess lung volume, capacity, rates of flow, and gas exchange. We will look at the Diffusion Capacity Tests (DLCO). DLCO: Measures how well oxygen and CO2 are exchanged between the lungs and the blood.
Measured: It will be measured at baseline, at 3, 6, and 12 months, and every other year till end of follow-up (60months))
Pulmonary function tests (PFTs)- Lungvolume measurement
Pulmonary function tests (PFTs) are a group of tests that measure how well your lungs are working. These tests assess lung volume, capacity, rates of flow, and gas exchange. We will look at the Lung Volumes and Capacities
- Total Lung Capacity (TLC): The total volume of air in the lungs after taking the deepest breath.
- Residual Volume (RV): The amount of air left in the lungs after a full exhalation.
- Functional Residual Capacity (FRC): The amount of air remaining in the lungs after normal exhalation.
- Inspiratory Capacity (IC): The maximum amount of air that can be inhaled after a normal exhalation.
Measured: It will be measured at baseline, at 3, 6, and 12 months, and every other year till end of follow-up (60months))
Biomarkers related to pulmonary fibrosis will be measured in plasma and serum
Blood will be taken from participants at the 8 different time points. A predefined panel of biomarkers related to pulmonary fibrosis will be measured in serum/plasma, urine, and, if available, bronchoalveolar lavage fluid. Biomarker levels will be correlated with the time to event (i.e., development of rapid progression or acute exacerbation) to identify biomarkers that predict rapid progression or acute exacerbation, as defined by the criteria by Raghu et al., (2022).
Measured: It will be measured at baseline, at 3, 6, and 12 months, and every other year till end of follow-up (60months))
Peripheral blood mononuclear cell (PBMC) populations in blood
Deep phenotyping of peripheral blood mononuclear cells (PBMCs) and, when available, BAL cells will be performed using flow cytometry, spectral flow, or cyTOF (cytometry by time of flight). A panel of surface and activation markers will define subsets of monocyte and lymphocyte populations. Data will be correlated to the time of the event.
Measured: It will be measured Will be measured at baseline, at 3, 6 months, 12 months, and every other year till end of follow-up (60months)
Exhaled breath analysis including volatile organic compounds
Exhaled breath analysis involves measurements of volatile organic compounds (VOCs) using gas chromatography-mass spectrometry (GC-MS) and electronic sensor detection of exhaled breath compounds in a non-invasive manner (breathing into a device). For all participants, VOCs will be measured using GC-MS (in house GC mass spectrometer)..
Measured: It will be measured at baseline, at 3, 6, and 12 months, and every other year till end of follow-up (60months))
Secondary outcomes (18)
Disease-relevant questionnaires: Exposure Questionnaire
During multiple visits, participants will be requested to complete the questionnaires below. The questionnaires that are not completed in the study center will be sent to the participants via email to fill out at home or bring to the clinic next visit. The Exposure questionnaire. Participants will be asked about their exposures and exposure risks. They are requested to answer the questions as completely as possible. The participant is asked about their current occupation and occupation history, as well as any present or past exposures to metals, fibers, chemicals, dust, smoke, fog/mist, gases, fumes, animal- or plant-materials, bacterial, viral or fungi contacts. Additionally, we will inquire about what kind of environment they have been living in and the duration of their residency. Other questions will cover hobbies, pesticide contact, and animal contact. The follow-up questionnaire has fewer questions.
Measured: Questionnaires will be filled in at baseline, at 6, and 12 months, and every other year till end of follow-up (60months))
Disease-relevant questionnaires: KBILD questionnaire.
During multiple visits, participants will be requested to complete the questionnaires below. The questionnaires that are not completed in the study center will be sent to the participants via email to fill out at home. The King's Brief Interstitial Lung Disease (KBILD) questionnaire is designed to assess the impact of the ILD on the participant's overall well-being and daily life. It can be used to monitor the progression of ILD, evaluate treatment effectiveness, and assess ongoing management. The KBILD questionnaire consists of 15 brief items. For more details, please visit https://www.kbild.com.
Measured: Questionnaires will be filled in at baseline, at 6, and 12 months, and every other year till end of follow-up (60months))
Disease-relevant questionnaires: Modified Medical Research Council Dyspnea score
During multiple visits, participants will be requested to complete the questionnaires below. The questionnaires that are not completed in the study center will be sent to the participants via email to fill out at home. The mMRC (Modified Medical Research Council) Dyspnea Scale is used to assess the level of baseline functional disability caused by dyspnea. The mMRC dyspnea scale ranges from grade 0 to 4, with 0 indicating minimal dyspnea. This longitudinal data is valuable for understanding the natural progression of ILDs and evaluating the effectiveness of long-term interventions.
Measured: Questionnaires will be filled in at baseline, at 6, and 12 months, and every other year till end of follow-up (60months))
Disease-relevant questionnaires: Visual analog scale (VAS)
During multiple visits, participants will be requested to complete the questionnaires below. The questionnaires that are not completed in the study center will be sent to the participants via email to fill out at home. The Visual analog scale (VAS) is a linear scoring method with a scale ranging from 0 to 10. A score of 0 represents no coughing symptoms, while a score of 10 represents the most severe coughing. The participant is asked to mark the severity of the cough on the scale based on self-perception.
Measured: Questionnaires will be filled in at baseline, at 6, and 12 months, and every other year till end of follow-up (60months))
Disease-relevant questionnaires: Fatigue Severity Scale (FSS)
During multiple visits, participants will be requested to complete the questionnaires below. The questionnaires that are not completed in the study center will be sent to the participants via email to fill out at home.
The Fatigue Severity Scale (FSS) will be used to determine the severity of fatigue in participants. The questionnaire contains nine items and should take approximately 5 minutes to complete. Fatigue is assessed through nine statements that can be scored on a 7-point scale, ranging from 1 (strongly disagree) to 7 (strongly agree). The total score, ranging from 9 to 63, will be divided by 9. A higher score indicated a higher level of fatigue.
Measured: Questionnaires will be filled in at baseline, at 6, and 12 months, and every other year till end of follow-up (60months))
Genomics analysis in blood.
Increasing evidence suggests that genetic factors play a significant role in the emergence of interstitial lung disease (ILD), particularly within the framework of familial clustering, as seen in cases of familial interstitial pneumonia (FIP)(Borie et al., 2019).
DNA and total RNA will be isolated from blood using the RNeasy DNA/RNA Universal kit (Qiagen). RNA will be used for generating the transcriptomic data, while DNA will be dedicated to GWAS analysis and methylome profiling. Whole genome transcriptome analysis will be conducted using state-of-the-art RNA sequencing.
Measured: Genomics are done once at baseline.
Epigenomics analysis in blood.
Increasing evidence suggests that genetic factors play a significant role in the emergence of interstitial lung disease (ILD), particularly within the framework of familial clustering, as seen in cases of familial interstitial pneumonia (FIP)(Borie et al., 2019).
DNA and total RNA will be isolated from blood using the RNeasy DNA/RNA Universal kit (Qiagen). RNA will be used for generating the transcriptomic data, while DNA will be dedicated to GWAS analysis and methylome profiling. Whole genome transcriptome analysis will be conducted using state-of-the-art RNA sequencing.
Measured: Epigonomics are done at baseline and 1 year after inclusion.
Transcriptome analysis in blood.
Increasing evidence suggests that genetic factors play a significant role in the emergence of interstitial lung disease (ILD), particularly within the framework of familial clustering, as seen in cases of familial interstitial pneumonia (FIP)(Borie et al., 2019).
Whole genome transcriptome analysis will be conducted using state-of-the-art RNA sequencing. RNAseq libraries will be generated from poly-A enriched RNA and sequenced on the Illumina Hiseq sequencer. After sequencing, the generated reads will be aligned to the UCSC human hg19 reference genomes using software programs such as the short-read mappers and splice-junction identifier TopHat. Differential gene expression analysis will be performed using the DESeq package. RNAseq offers the advantage of detecting all expressed genes without any "a priori" selection through unlined microarray-based gene expression analysis.
Measured: Transcriptome is performed at baseline, 6 months and 1 year after inclusion.
Proteome analysis in bronchoalveolar lavage fluid
Biomarkerpanel related to pulmonary fibrosis will be measured in bronchoalveolar lavage fluid. A panel of biomarkers related to pulmonary fibrosis will be measured in BALF. The biomarkers will be determined using a biased approach using the Luminex® Instrument (Austin, USA) and unbiased approach using Olink® (Uppsala, Sweden) techniques. Units of Measure will be concentrations of the different proteins in picograms/mililiters
Measured: In Group 3, thirty participants will undergo bronchoalveolar lavage at baseline. Additional procedures may be performed during the follow-up period if clinically indicated and will be added to samples. .
Microbiome analyses in stool and nasal swabs.
The gut and respiratory microbiomes play an important role in regulating immune responses. The research study will assess the overall microbial metabolic activity and changes in microbiome composition by analyzing fecal and nasal samples from each participant.
Measured: Once in first year
Concentration of Biomarkers in Exhaled Particles (Collected via Impaction)
Small droplets, or particles, that arise when small airways close and re-open, are collected from the exhaled air and sampled by impaction (PExA technology). Biomarkers from exhaled air particles, collected through impaction, will be analyzed using proteomics platform assays or Enzyme-Linked Immunosorbent Assay (ELISA). The concentration of specific biomarkers (e.g., proteins, cytokines) will be quantified. Unit of Measure: Concentration (pg/mL or ng/mL).. For more details, visit https://pexa.se/en/.
Measured: From moment of inclusion every year untill end of follow-up at 60 months.
Identification of Compounds in Exhaled Particles via Mass Spectrometry (MS)
Small droplets, or particles, that arise when small airways close and re-open, are collected from the exhaled air and sampled by impaction. Exhaled particles will be analyzed using Mass Spectrometry (MS) to identify and quantify specific compounds or molecular signatures. Concentration (μg/mL or relative abundance). For more details, visit https://pexa.se/en/.
Measured: From moment of inclusion every year untill end of follow-up at 60 months.
Separation and Quantification of Compounds in Exhaled Particles Using Liquid Chromatography (LC) and High-Performance Liquid Chromatography (HPLC)
Small droplets, or particles, that arise when small airways close and re-open, are collected from the exhaled air and sampled by impaction. Liquid Chromatography (LC) and High-Performance Liquid Chromatography (HPLC) will be used to separate and quantify compounds present in exhaled air samples.
Unit of Measure: Concentration (ng/mL or μg/mL). For more details, visit https://pexa.se/en/.
Measured: From moment of inclusion every year untill end of follow-up at 60 months.
Metabolome analyses in blood.
Metabolomics is a rapidly evolving field, and advancements in technology and analytical methods continue to enhance our understanding of the metabolome and its role in human health and disease. By profiling the metabolites present in blood, we can gain insights into metabolic pathways, identify disease signatures, monitor treatment response, and uncover potential therapeutic targets for ILD. IPF is associated with a distinct circulating metabolome (Hesslinger et al., 2019).
Blood samples will be collected via venipuncture at ILD centers to profile metabolites associated with idiopathic pulmonary fibrosis (IPF). Specific biomarkers to be assessed include: Amino acids (e.g., glutamine, tryptophan), Lipids (e.g., triglycerides, phospholipids), Organic acids (e.g., lactate, citric acid), Nucleotides (e.g., ATP, uric acid). These metabolites will provide insights into metabolic pathways. Concentration (μmol/L, ng/mL, or similar, as appropriate for each metabolite).
Measured: Twice in the first year of inclusion; baseline and at 6 months.
Metabolome analyses in urine
Metabolomics is a rapidly evolving field, and advancements in technology and analytical methods continue to enhance our understanding of the metabolome and its role in human health and disease. By profiling the metabolites present in blood, we can gain insights into metabolic pathways, identify disease signatures, monitor treatment response, and uncover potential therapeutic targets for ILD. IPF is associated with a distinct circulating metabolome (Hesslinger et al., 2019).
Urine samples will be collected at home and stored at -80ºC in the biobank for metabolome and biomarker analysis. Specific biomarkers to be assessed include: Creatinine, Electrolytes (e.g., sodium, potassium), Organic metabolites (e.g., hippurate, citrate). These biomarkers will help identify metabolic changes related to ILD. Unit of Measure: Concentration (mmol/L, mg/mL, or similar, as appropriate for each metabolite).
Measured: Twice in the first year of inclusion; baseline and at 6 months.
Personal exposure to environmental pollutants using the Ultrasonic Personal Air Sampler
External exposome factors such as concentrations of ambient air pollution and other environmental pollutants will be quantified. Time-weighted measurements of PM2.5 will be collected using personal samplers.
Measured: Exposome will be measured twice in first year, dependant on season (for most patients at 6 and 1 year follow-up))
External exposome analyses using Silicon wristbands
These wristbands collect exposome particles from the surrounding air in the participant's living environment. The wristbands will be worn for 4 to 5 days and then stored in a sealed bag to be returned to field workers. External exposome factors such as concentrations of ambient air pollution and other environmental pollutants will be quantified. Time-weighted measurements of PM2.5 will be collected.
Measured: Exposome will be measured twice in first year, dependant on season (for most patients at 6 and 1 year follow-up))
External exposome analyses using a Sniffer-bike
Sniffer-bike will be placed at the home of the patient and measures external exposome factors such as concentrations of ambient air pollution and other environmental pollutants, these will be quantified. Time-weighted measurements of PM2.5 will be collected using these stationary samplers.
Measured: Exposome will be measured twice in first year, dependant on season (for most patients at 6 and 1 year follow-up))
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Oct 2024
- Study start1 Nov 2024
- Primary completion1 Oct 2028 (estimated)
- Study completion1 Oct 2031 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Interstitial Lung DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 450 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Amsterdam UMC, location VUmc
- Sponsor type
- University, hospital or other
- Collaborators
- AbbVie, Boehringer Ingelheim
- Responsible party
- Principal investigator, Jan Willem Duitman, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Investigators
- Esther Nossent, MD, Principal investigator, Amsterdam UMC, locatie VUmcJan Willem Duitman, PhD, Principal investigator, Amsterdam UMC, locatie VUmcAnke-Hilse Maitland-van der Zee, PhD, Principal investigator, Amsterdam UMC, locatie VUmc
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06644144
- Sponsor's protocol ID
- 2023.0591
- Other IDs
- NL84006.018.23
- Acronym
- P4O2-ILD
- Status last verified
- May 2026
- First submitted
- 23 Sep 2024
- Last updated
- 11 May 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: The study is part of the P4O2 consortium, which focuses on chronic illnesses. Access to data is strictly regulated and provided only to answer research questions that emerge from an approved project proposal. The Data Committee evaluates whether a research question aligns with the original proposal and determines the specific conditions under which access is granted. Consortium members receive pseudonymized data for research and development purposes. These partners must sign a data sharing agreement before accessing the data. Private companies within the consortium may only receive anonymous data for commercial purposes. Private partners outside the consortium can request an analysis, but the outcome is limited to a report or scientific publication. For commercial purposes, these external private companies are permitted to receive only pseudonymized data, ensuring strict adherence to data protection protocols and ethical standards.
Study at a glance
From the registry record, last updated by the sponsor on 11 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Early Identification of Progressive Pulmonary Fibrosis, Precision Medicine for More Oxygen - ILD Extension.
- ClinicalTrials.gov ID
- NCT06644144
- Acronym / sponsor ID
- P4O2-ILD / 2023.0591
- Conditions
- Interstitial Lung Disease, Pulmonary Fibrosis, Interstitial Lung Fibrosis, IPF, Pulmonary Fibrosis, Idiopathic, Pulmonary Fibrosis Idiopathic Familial
- Keywords
- Interstitial Lung Disease, Interstitial Lung Abnormalities, Progressive Pulmonary Fibrosis
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 450 participants (estimated)
- Lead sponsor
- Amsterdam UMC, location VUmcUniversity, hospital or other
- Collaborators
- AbbVie, Boehringer Ingelheim
- Study start
- 1 Nov 2024 (actual)
- Primary completion
- 1 Oct 2028 (estimated)
- Study completion
- 1 Oct 2031 (estimated)
- First posted
- 16 Oct 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to identify early biomarkers that can predict the development of progressive pulmonary fibrosis (PPF) in participants with interstitial lung diseases (ILDs). The participant population includes adults diagnosed with idiopathic pulmonary fibrosis (IPF), familial pulmonary fibrosis (FPF), other fibrotic ILDs, and interstitial lung abnormalities (ILA).
The main questions it aims to answer are:
- What biomarkers and risk factors are linked to fibrosis progression or can predict rapid worsening and sudden flare-ups in IPF and FPF patients?
- What biomarkers and risk factors can predict the development of a PPF phenotype in different types of ILD?
- What biomarkers and risk factors can help identify ILA patients who may develop significant ILD?
- What biomarkers and risk factors can predict how well ILD patients will respond to treatment?
Researchers will compare the outcomes between participants diagnosed with IPF/FPF, other fibrotic ILDs, and ILA to see if early detection biomarkers differ among these groups.
Participants will:
- Undergo blood sampling.
- Perform lung function tests.
- Have CT scans.
- Perform breath analysis
- Participate in exposome and microbiome analyses.
- Complete questionnaires.
- A subgroup of participants will be offered bronchoscopy.
Detailed description
Included participants will complete several study visits to collect clinical data and biological samples. Study visits will be performed at baseline, 3, 6, 12, 24, 36, 48 and 60 months, with a 2-month time window for follow-up visits. These time points are aligned with the standard clinical follow-up visits outlined in the ILD Care Path Protocol of Amsterdam UMC.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Idiopathic Pulmonary Fibrosis/Familial Pulmonary Fibrosis | – | Other: No Interventions |
| fibrotic ILD | – | Other: No InterventionsPatients with a diagnosis of: chronic Hypersensitivity Pneumonitis (cHP), unclassifiable ILD (uILD), idiopathic NSIP or CTD-ILD. |
| Interstitial Lung Abnormalities | – | Other: No Interventions |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The P4O2 ILD-extension is a non-interventional prospective observational cohort study that will include a minimum of 450 participants, divided intro three groups (1) 150 participants diagnosed with idiopathic pulmonary fibrosis (IPF) or familial pulmonary fibrosis (FPF); (2) 150 participants diagnosed with other fibrotic ILDs (fILD), including fibrotic hypersensitivity pneumonitis (fHP), idiopathic non-specific interstitial pneumonia (iNSIP), connective tissue disease (CTD)-ILD, and unclassifiable ILD (uILD); and (3) 150 participants diagnosed with interstitial lung abnormalities (ILA).
Key inclusion criteria (9 listed)
- Diagnosis of (1) idiopathic pulmonary fibrosis (IPF), familial pulmonary fibrosis (FPF), (2) other fibrotic ILDs (fILD), including fibrotic hypersensitivity pneumonitis (fHP), idiopathic non-specific interstitial pneumonia (iNSIP), connective tissue disease (CTD)-ILD, and unclassifiable ILD (uILD); or (3) interstitial lung abnormalities (ILA).
- Meeting all the following criteria during the screening period:
- Able to provide written informed consent as approved by the independent ethics committee.
- Able to undergo a CT scan and perform PFT.
- Age \> 18 years and \< 80 years.
Key exclusion criteria (5 listed)
- Combined pulmonary fibrosis and emphysema (CPFE) diagnosis
- Chronic obstructive lung disease (COPD) with an FEV1/FVC \<70%.
- Uncontrolled severe asthma.
- Active malignancy, except for squamous cell carcinoma of the skin, low-risk breast cancer, and low-risk prostate cancer.
- Pregnancy or lactating.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| No InterventionsNo intervention so not applicable. | Other | Idiopathic Pulmonary Fibrosis/Familial Pulmonary Fibrosis, Interstitial Lung Abnormalities, fibrotic ILD |
Primary outcome
Inflammatory and fibrosis extent assessed by HRCT
Time frame: A baseline HRCT scan will be performed during screening. Following inclusion in the study, HRCT scans will be repeated annually, starting one year after the initial scan, and continuing each year until the end of follow-up (at 5 years))
High-Resolution Computed Tomography (HRCT) is an advanced imaging technique used to obtain detailed images of the lungs and chest. Unlike standard CT scans, HRCT uses thin slices and special algorithms to produce high-resolution images that provide more precise visualization of lung structures, making it particularly useful for diagnosing and evaluating various lung conditions. The Inflammatory and Fibrosis extent will be analyzed by using artificial intelligence software.
Pulmonary function tests (PFTs)- Spirometry volumes
Time frame: It will be measured at baseline, at 3, 6, and 12 months, and every other year till end of follow-up (60months))
Pulmonary function tests (PFTs) are a group of tests that measure how well your lungs are working. These tests assess lung volume, capacity, rates of flow, and gas exchange. We will look at the following values: 1. Spirometry Values * Forced Vital Capacity (FVC): The total amount of air exhaled after taking the deepest breath possible. * Forced Expiratory Volume in 1 Second (FEV1): The amount of air forcefully exhaled in one second.
Pulmonary function tests (PFTs)- DLCO measurement
Time frame: It will be measured at baseline, at 3, 6, and 12 months, and every other year till end of follow-up (60months))
Pulmonary function tests (PFTs) are a group of tests that measure how well your lungs are working. These tests assess lung volume, capacity, rates of flow, and gas exchange. We will look at the Diffusion Capacity Tests (DLCO). DLCO: Measures how well oxygen and CO2 are exchanged between the lungs and the blood.
Pulmonary function tests (PFTs)- Lungvolume measurement
Time frame: It will be measured at baseline, at 3, 6, and 12 months, and every other year till end of follow-up (60months))
Pulmonary function tests (PFTs) are a group of tests that measure how well your lungs are working. These tests assess lung volume, capacity, rates of flow, and gas exchange. We will look at the Lung Volumes and Capacities * Total Lung Capacity (TLC): The total volume of air in the lungs after taking the deepest breath. * Residual Volume (RV): The amount of air left in the lungs after a full exhalation. * Functional Residual Capacity (FRC): The amount of air remaining in the lungs after normal exhalation. * Inspiratory Capacity (IC): The maximum amount of air that can be inhaled after a normal exhalation.
Biomarkers related to pulmonary fibrosis will be measured in plasma and serum
Time frame: It will be measured at baseline, at 3, 6, and 12 months, and every other year till end of follow-up (60months))
Blood will be taken from participants at the 8 different time points. A predefined panel of biomarkers related to pulmonary fibrosis will be measured in serum/plasma, urine, and, if available, bronchoalveolar lavage fluid. Biomarker levels will be correlated with the time to event (i.e., development of rapid progression or acute exacerbation) to identify biomarkers that predict rapid progression or acute exacerbation, as defined by the criteria by Raghu et al., (2022).
Peripheral blood mononuclear cell (PBMC) populations in blood
Time frame: It will be measured Will be measured at baseline, at 3, 6 months, 12 months, and every other year till end of follow-up (60months)
Deep phenotyping of peripheral blood mononuclear cells (PBMCs) and, when available, BAL cells will be performed using flow cytometry, spectral flow, or cyTOF (cytometry by time of flight). A panel of surface and activation markers will define subsets of monocyte and lymphocyte populations. Data will be correlated to the time of the event.
Exhaled breath analysis including volatile organic compounds
Time frame: It will be measured at baseline, at 3, 6, and 12 months, and every other year till end of follow-up (60months))
Exhaled breath analysis involves measurements of volatile organic compounds (VOCs) using gas chromatography-mass spectrometry (GC-MS) and electronic sensor detection of exhaled breath compounds in a non-invasive manner (breathing into a device). For all participants, VOCs will be measured using GC-MS (in house GC mass spectrometer)..
18 secondary outcomes
Disease-relevant questionnaires: Exposure Questionnaire
Time frame: Questionnaires will be filled in at baseline, at 6, and 12 months, and every other year till end of follow-up (60months))
Disease-relevant questionnaires: KBILD questionnaire.
Time frame: Questionnaires will be filled in at baseline, at 6, and 12 months, and every other year till end of follow-up (60months))
Disease-relevant questionnaires: Modified Medical Research Council Dyspnea score
Time frame: Questionnaires will be filled in at baseline, at 6, and 12 months, and every other year till end of follow-up (60months))
Disease-relevant questionnaires: Visual analog scale (VAS)
Time frame: Questionnaires will be filled in at baseline, at 6, and 12 months, and every other year till end of follow-up (60months))
Disease-relevant questionnaires: Fatigue Severity Scale (FSS)
Time frame: Questionnaires will be filled in at baseline, at 6, and 12 months, and every other year till end of follow-up (60months))
Genomics analysis in blood.
Time frame: Genomics are done once at baseline.
Epigenomics analysis in blood.
Time frame: Epigonomics are done at baseline and 1 year after inclusion.
Transcriptome analysis in blood.
Time frame: Transcriptome is performed at baseline, 6 months and 1 year after inclusion.
Proteome analysis in bronchoalveolar lavage fluid
Time frame: In Group 3, thirty participants will undergo bronchoalveolar lavage at baseline. Additional procedures may be performed during the follow-up period if clinically indicated and will be added to samples. .
Microbiome analyses in stool and nasal swabs.
Time frame: Once in first year
Concentration of Biomarkers in Exhaled Particles (Collected via Impaction)
Time frame: From moment of inclusion every year untill end of follow-up at 60 months.
Identification of Compounds in Exhaled Particles via Mass Spectrometry (MS)
Time frame: From moment of inclusion every year untill end of follow-up at 60 months.
Separation and Quantification of Compounds in Exhaled Particles Using Liquid Chromatography (LC) and High-Performance Liquid Chromatography (HPLC)
Time frame: From moment of inclusion every year untill end of follow-up at 60 months.
Metabolome analyses in blood.
Time frame: Twice in the first year of inclusion; baseline and at 6 months.
Metabolome analyses in urine
Time frame: Twice in the first year of inclusion; baseline and at 6 months.
Personal exposure to environmental pollutants using the Ultrasonic Personal Air Sampler
Time frame: Exposome will be measured twice in first year, dependant on season (for most patients at 6 and 1 year follow-up))
External exposome analyses using Silicon wristbands
Time frame: Exposome will be measured twice in first year, dependant on season (for most patients at 6 and 1 year follow-up))
External exposome analyses using a Sniffer-bike
Time frame: Exposome will be measured twice in first year, dependant on season (for most patients at 6 and 1 year follow-up))
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 May 2026.
- Individual participant dataSharing planned: Undecided. The study is part of the P4O2 consortium, which focuses on chronic illnesses. Access to data is strictly regulated and provided only to answer research questions that emerge from an approved project proposal. The Data Committee evaluates whether a research question aligns with the original proposal and determines the specific conditions under which access is granted. Consortium members receive pseudonymized data for research and development purposes. These partners must sign a data sharing agreement before accessing the data. Private companies within the consortium may only receive anonymous data for commercial purposes. Private partners outside the consortium can request an analysis, but the outcome is limited to a report or scientific publication. For commercial purposes, these external private companies are permitted to receive only pseudonymized data, ensuring strict adherence to data protection protocols and ethical standards.
Related trials for Interstitial Lung Disease
RecruitingPhase 3
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Pulmonary Hypertension, Interstitial Lung Disease
RecruitingPhase 2
Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders
Langerhan's Cell Histiocytosis, Juvenile Xanthogranuloma
RecruitingPhase 2
Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
RecruitingObservational study
Role of Genetic Factors in the Development of Lung Disease
Cystic Fibrosis, Pulmonary Fibrosis
RecruitingPhase 3
Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging
Allogeneic Stem Cell Transplantation, Lung Allograft Transplantation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Esther Nossent, MD principal investigator
Amsterdam UMC, locatie VUmc
Jan Willem Duitman, PhD principal investigator
Amsterdam UMC, locatie VUmc
Anke-Hilse Maitland-van der Zee, PhD principal investigator
Amsterdam UMC, locatie VUmc
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Interstitial Lung Disease and Pulmonary Fibrosis, run by Amsterdam UMC, location VUmc at 1 site in Netherlands.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 11 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jan Willem Duitman, PhD (0205668753 ext. +31, j.w.duitman@amsterdamumc.nl), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Inflammatory and fibrosis extent assessed by HRCT (time frame: A baseline HRCT scan will be performed during screening. Following inclusion in the study, HRCT scans will be repeated annually, starting one year after the initial scan, and continuing each year until the end of follow-up (at 5 years))). The study lists 7 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 May 2026.